Atlas Trials

Xentria, Inc.

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Xentria, Inc.

RecordFirmDate
A Seamless, Adaptive Multiple-Ascending-Dose and Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations (NCT07680166)Xentria, Inc.2026-10-30
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(L), US-Humalog®, and EU-Humalog® (NCT07165652)Xentria, Inc.2025-10-13
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® (NCT06504966)Xentria, Inc.2025-10-01
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus® (NCT06627478)Xentria, Inc.2024-10-29
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid® (NCT06492226)Xentria, Inc.2024-07-30
Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® (NCT06310824)Xentria, Inc.2024-06-05
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis (NCT06169397)Xentria, Inc.2024-03-01
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis (NCT05890729)Xentria, Inc.2023-11-10
Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants (NCT04971395)Xentria, Inc.2021-06-25

Track Xentria, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.